Literature DB >> 12782212

Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats.

J Srinivasan1, B Suresh, M Ramanathan.   

Abstract

The effect of angiotensin-converting enzyme (ACE) inhibitor enalapril (EPL) (2 and 4 mg/kg), angiotensin (AT) II receptor antagonist losartan (LRN) (5 and 10 mg/kg), and anxiolytic drug diazepam (DZP) (0.5 mg/kg) on anxiety parameters were evaluated in experimentally induced renal hypertensive rats (RHR). Renal hypertension was induced in Wistar strain male albino rats weighing 200-250 g by following the method of Goldblatt. The animals having systolic blood pressure more than 180-210 mm Hg were subjected to open-field exploratory behaviour, elevated plus maze behaviour, and social interaction tests of anxiety. The RHR showed hyperactivity in open-field behaviour and anxiogenicity in elevated plus maze and social interaction tests. Losartan (5 and 10 mg/kg) and DZP (0.5 mg/kg) significantly attenuated the hyperactivity and anxiogenic behaviour in experimentally induced hypertensive rats and induced anxiolysis in normotensive rats (NTR). Enalapril reversed the hypertension-induced alteration only at higher dose (4 mg/kg) and failed to show any effect in NTR. It can be concluded that renin angiotensin aldosterone system (RAAS) has a significant role on behaviour, and LRN has shown better effect in reversing the hyperactivity and anxiogenicity in the experimentally induced hypertensive rats, indicating a possible role of AT receptor in the mediation of anxiolysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782212     DOI: 10.1016/s0031-9384(03)00036-2

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  8 in total

1.  Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy.

Authors:  Jana D Tchekalarova; Natasha Ivanova; Dimitrina Atanasova; Daniela M Pechlivanova; Nikolai Lazarov; Lidia Kortenska; Rumiana Mitreva; Valentin Lozanov; Alexander Stoynev
Journal:  Cell Mol Neurobiol       Date:  2015-10-13       Impact factor: 5.046

2.  Strain differences and the role of AT(1) receptor expression in anxiety.

Authors:  Bruno J Golding; Andrew Dj Overall; Paul R Gard
Journal:  Int J Mol Epidemiol Genet       Date:  2010-12-26

3.  Angiotensin II AT1 receptor blockade ameliorates brain inflammation.

Authors:  Julius Benicky; Enrique Sánchez-Lemus; Masaru Honda; Tao Pang; Martina Orecna; Juan Wang; Yan Leng; De-Maw Chuang; Juan M Saavedra
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

4.  Facilitation of TRKB Activation by the Angiotensin II Receptor Type-2 (AT2R) Agonist C21.

Authors:  Liina Laukkanen; Cassiano R A F Diniz; Sebastien Foulquier; Jos Prickaerts; Eero Castrén; Plinio C Casarotto
Journal:  Pharmaceuticals (Basel)       Date:  2021-08-06

Review 5.  Cardiovascular therapeutics: A new potential for anxiety treatment?

Authors:  Kristina Repova; Silvia Aziriova; Kristina Krajcirovicova; Fedor Simko
Journal:  Med Res Rev       Date:  2022-01-06       Impact factor: 12.388

6.  Fear-potentiated behaviour is modulated by central amygdala angiotensin II AT1 receptors stimulation.

Authors:  Maria de los Angeles Marinzalda; Pablo A Pérez; Pascual A Gargiulo; Brenda S Casarsa; Claudia Bregonzio; Gustavo Baiardi
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

Review 7.  The renin-angiotensin system: a possible new target for depression.

Authors:  João Vian; Círia Pereira; Victor Chavarria; Cristiano Köhler; Brendon Stubbs; João Quevedo; Sung-Wan Kim; André F Carvalho; Michael Berk; Brisa S Fernandes
Journal:  BMC Med       Date:  2017-08-01       Impact factor: 8.775

8.  Effects of Gladiolus dalenii on the Stress-Induced Behavioral, Neurochemical, and Reproductive Changes in Rats.

Authors:  David Fotsing; Gwladys T Ngoupaye; Agnes C Ouafo; Stephanie K J Njapdounke; Yongabi A Kenneth; Elisabeth Ngo Bum
Journal:  Front Pharmacol       Date:  2017-09-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.